JP2016503063A - がんの治療に関する方法及び組成物 - Google Patents

がんの治療に関する方法及び組成物 Download PDF

Info

Publication number
JP2016503063A
JP2016503063A JP2015549772A JP2015549772A JP2016503063A JP 2016503063 A JP2016503063 A JP 2016503063A JP 2015549772 A JP2015549772 A JP 2015549772A JP 2015549772 A JP2015549772 A JP 2015549772A JP 2016503063 A JP2016503063 A JP 2016503063A
Authority
JP
Japan
Prior art keywords
isc
cetuximab
cancer
combination
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015549772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503063A5 (enExample
Inventor
イー． アレン，ジョシュア
イー． アレン，ジョシュア
エス． エル−デイーリー，ウァフィック
エス． エル−デイーリー，ウァフィック
ケー． シャーマ，アルン
ケー． シャーマ，アルン
ジー． アミン，シャントゥー
ジー． アミン，シャントゥー
イルビー，ロザリン
Original Assignee
ザ ペン ステイト リサーチ ファンデーション
ザ ペン ステイト リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ペン ステイト リサーチ ファンデーション, ザ ペン ステイト リサーチ ファンデーション filed Critical ザ ペン ステイト リサーチ ファンデーション
Publication of JP2016503063A publication Critical patent/JP2016503063A/ja
Publication of JP2016503063A5 publication Critical patent/JP2016503063A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015549772A 2012-12-20 2013-12-20 がんの治療に関する方法及び組成物 Pending JP2016503063A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740126P 2012-12-20 2012-12-20
US61/740,126 2012-12-20
PCT/US2013/076869 WO2014100565A1 (en) 2012-12-20 2013-12-20 Methods and compositions relating to treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016503063A true JP2016503063A (ja) 2016-02-01
JP2016503063A5 JP2016503063A5 (enExample) 2017-01-26

Family

ID=49950064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549772A Pending JP2016503063A (ja) 2012-12-20 2013-12-20 がんの治療に関する方法及び組成物

Country Status (10)

Country Link
US (1) US20150328310A1 (enExample)
EP (1) EP2934583A1 (enExample)
JP (1) JP2016503063A (enExample)
KR (1) KR20150099588A (enExample)
CN (1) CN105007940B (enExample)
AU (1) AU2013361164A1 (enExample)
CA (1) CA2894547A1 (enExample)
RU (1) RU2015129366A (enExample)
SG (1) SG11201504779YA (enExample)
WO (1) WO2014100565A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109600989A (zh) * 2016-06-29 2019-04-09 普林斯匹亚生物制药公司 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
US12178818B2 (en) 2019-10-14 2024-12-31 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US12410176B2 (en) 2020-01-22 2025-09-09 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128189A1 (en) * 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128189A1 (en) * 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACTA CHEMICA SCANDINAVICA, vol. B41, JPN6017031768, 1987, pages 29 - 33, ISSN: 0003783506 *
CHEMBIOCHEM, vol. 9, JPN6017031770, 2008, pages 729 - 747, ISSN: 0003783507 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.28,no.15_suppl, JPN6017031764, 2010, pages 3573, ISSN: 0003783504 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.30，no.15_suppl, JPN6017031766, 2012, pages 3558, ISSN: 0003783505 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109600989A (zh) * 2016-06-29 2019-04-09 普林斯匹亚生物制药公司 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
JP2019519581A (ja) * 2016-06-29 2019-07-11 プリンシピア バイオファーマ インコーポレイテッド ２−［３−［４−アミノ−３−（２−フルオロ−４−フェノキシ−フェニル）ピラゾロ［３，４−ｄ］ピリミジン−１−イル］ピペリジン−１−カルボニル］−４−メチル−４−［４−（オキセタン−３−イル）ピペラジン−１−イル］ペント−２−エネニトリルの放出調節製剤
JP7129704B2 (ja) 2016-06-29 2022-09-02 プリンシピア バイオファーマ インコーポレイテッド ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペント－２－エネニトリルの放出調節製剤
US11872229B2 (en) 2016-06-29 2024-01-16 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US12336999B2 (en) 2016-06-29 2025-06-24 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl]pent-2-enenitrile
US12178818B2 (en) 2019-10-14 2024-12-31 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US12410176B2 (en) 2020-01-22 2025-09-09 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Also Published As

Publication number Publication date
CN105007940B (zh) 2017-08-25
RU2015129366A (ru) 2017-01-25
SG11201504779YA (en) 2015-07-30
KR20150099588A (ko) 2015-08-31
CN105007940A (zh) 2015-10-28
WO2014100565A1 (en) 2014-06-26
EP2934583A1 (en) 2015-10-28
CA2894547A1 (en) 2014-06-26
AU2013361164A1 (en) 2015-07-02
US20150328310A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
JP7600286B2 (ja) 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導
RU2605335C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2023060196A5 (enExample)
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
US20060135441A1 (en) Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
KR20180022926A (ko) 암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
JP2021152076A (ja) Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ
US10813931B2 (en) Methods and compositions relating to the treatment of cancer
JP2016503063A (ja) がんの治療に関する方法及び組成物
US7468355B2 (en) Methods for inhibiting cancer and scar formation
US20190111053A1 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
US10668078B2 (en) Methods and compositions for treating mesothelioma and small lung cancer that express midkine
KR20100099128A (ko) 개선된 항암치료
US10568873B1 (en) Safranal-sorafenib combination therapy for liver cancer
KR20160086962A (ko) 삼중 음성 유방 암 치료를 위해 카보플라틴과 병용된 벨리파리브
US20240148688A1 (en) Methods for treating and ameliorating cancer
TW202400158A (zh) 以μ-阿片受體拮抗劑治療癌症及其他病症的方法
WO2015015306A2 (en) Method for targeting vascular rhoj for inhibiting tumor angiogenesis
US20240390360A1 (en) Therapeutic Combinations Of Orally Administered Paclitaxel, A P-gp Inhibitor, And A Checkpoint Inhibitor For The Treatment Of Solid Tumors
CN109303919B (zh) Akt抑制剂在制备增强石蒜碱的抗肝癌活性药物中的应用
Casadevall Aguilar et al. mTOR inhibition and T-DM1 in HER2-positive breast cancer
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
JP2023059508A (ja) 悪性中皮腫の治療薬
UA97504C2 (uk) Спосіб зниження ризику виникнення або відстрочення виникнення раку у суб'єкта із застосуванням анти-vegf антитіла
KR20210097139A (ko) 데비미스타트를 사용하는 급성 골수성 백혈병을 치료하기 위한 치료적 방법 및 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180425